Bluebird Bio takes gene therapy into EMA's adaptive pathways pilot
This article was originally published in Scrip
Executive Summary
A total of 58 products have been submitted as potential candidates for the European Medicines Agency's adaptive pathways pilot, but the US company, bluebird bio, appears to be the first firm to have formally announced that it is taking this particular approach to approval.